Spirulina, Ceramide, and Apoptosis Signalling.

Ceramide as a Pro-Apoptotic Second Messenger

Ceramide (N-acylsphingosine) is generated by neutral sphingomyelinase 2 (nSMase2/SMPD3; plasma membrane-associated; Mg²&sup+;-dependent) in response to TNF-α, FasL, IL-1β, ROS, and UV. Ceramide activates protein phosphatase 2A (PP2A; Ser/Thr phosphatase; IC50 for ceramide activation ~1–5 μM) → PP2A dephosphorylates PKB/Akt Ser473 and Thr308, suppressing survival signalling. Ceramide also directly binds and activates kinase suppressor of Ras 1 (KSR1), facilitating Raf-1→MEK→ERK signalling in some contexts, and directly inhibits the anti-apoptotic Bcl-2/Bcl-xL by disrupting their interaction with the outer mitochondrial membrane. Ceramide inserts into lipid bilayers, forming ceramide-enriched membrane platforms (CEPs) that cluster death receptors (Fas/CD95, TNFR1), amplifying DISC (death-inducing signalling complex) assembly → caspase-8 activation → truncated Bid (tBid) → Bax/Bak outer mitochondrial membrane permeabilisation (MOMP).

JNK/p38 MAPK Stress Kinase Axis

Parallel to ceramide, TNF-α/IL-1β/ROS activate MAP3K5 (ASK1; apoptosis signal-regulating kinase 1) → MKK4/MKK7 → JNK1/2 Thr183/Tyr185; and MAP3K3 (MEKK3) → MKK3/MKK6 → p38α/β Thr180/Tyr182. ASK1 is normally kept inactive by thioredoxin 1 (TRX1) binding to ASK1 Cys17 and by 14-3-3 binding; oxidation of TRX1 Cys32/35 releases ASK1 → ASK1 autophosphorylation → JNK/p38 activation. JNK phosphorylates Bcl-2 Ser70 (pro-survival loop disrupted), c-Jun Ser63/73 (AP-1 ↑), and Bim Ser65 (stabilised). p38 phosphorylates MK2 (MNK2; MAPKAP-K2) → Hsp27 Ser15/78/82 disaggregation and HSF1 Ser121 (inhibitory). Both JNK and p38 phosphorylate p53 Ser15 and Ser20, stabilising p53→PUMA/NOXA→Bax/Bak activation. JNK also phosphorylates IRS-1 Ser307, linking stress to insulin resistance.

Intrinsic Apoptosis: Bcl-2 Family and Caspase Cascade

MOMP is controlled by the Bcl-2 family: anti-apoptotic (Bcl-2, Bcl-xL, Mcl-1) vs. pro-apoptotic effectors (Bax, Bak) and BH3-only activators (Bim, Puma, Noxa, tBid). Bax Thr167 phosphorylation by Akt inhibits Bax insertion; ceramide-driven Akt ↓ removes this brake. Cytochrome c release → Apaf-1 WD40 → conformational change → heptameric apoptosome → pro-caspase-9 (Asp315 autoprocessing) → caspase-9 → pro-caspase-3/7 (executioner) → PARP1 cleavage (Asp214), lamin A/C, and ICAD (inhibitor of CAD DNase). Inhibitor of apoptosis proteins (IAPs; XIAP Lys297 BIR2 domain binds caspase-3; BIR3 binds caspase-9) provide a final brake; Smac/DIABLO released from mitochondria relieves XIAP inhibition. Caspase-8 cleaves Bid at Asp59 → tBid→Bax activation, connecting extrinsic (death receptor) to intrinsic pathways.

Spirulina’s Mechanistic Actions

• nSMase2 ↓ → ceramide ↓: PCB → Nox2/ROS ↓ → nSMase2 activity ↓ 25–40% (Mg²&sup+;/ROS-sensitive Cys-containing activation domain) → ceramide ↓ 20–35% → PP2A activation ↓ → Akt Ser473/Thr308 phosphorylation maintained → Bax Thr167 inhibitory phosphorylation preserved.
• Nrf2 → TRX1 → ASK1 inhibition: Nrf2→TXNRD1/TRX1 ↑ → TRX1 Cys32/35 reduced → ASK1-TRX1 complex maintained → ASK1 autophosphorylation ↓ → JNK Thr183/Tyr185 ↓ 25–40%; p38 Thr180/Tyr182 ↓ 20–35%.
• NF-κB ↓ → TNF-α/FasL ↓: Reduces extrinsic apoptotic ligand production → DISC assembly ↓ → caspase-8 ↓ → tBid ↓ → MOMP ↓.
• Bcl-2/Bcl-xL stabilisation: AMPK→mTORC1↓→4E-BP1↓ maintains cap-independent Bcl-2 IRES translation; Nrf2→NQO1→NAD&sup+; supports Bcl-2 Ser70 phosphorylation (PKCδ-mediated survival loop). Bcl-2 +20–35% in spirulina-treated non-cancerous cell models; Bax:Bcl-2 ratio ↓ 25–40%.
• Cytochrome c / caspase cascade ↓: Mitochondrial membrane potential (Δψm) preserved ↑ 20–30% (SIRT3→complex I/SOD2); cytochrome c release ↓ 30–45%; caspase-9 activity ↓ 30–50%; caspase-3 ↓ 30–50%; PARP1 cleavage ↓ in cardiomyocyte I/R and neuronal ROS models.
• p53 pathway: SIRT1→p53 Lys382 deacetylation ↓ → p53 transcriptional activity ↓ → PUMA/NOXA ↓ (protective in non-cancerous tissue; note: p53 suppression in cancer cells would be undesirable — spirulina effects are context-dependent).

Clinical Correlates and Dosing

In cardiomyocyte ischaemia/reperfusion (I/R) models, spirulina extract (50–200 mg/kg) reduced infarct size 25–40% and caspase-3 activity 30–50%; Δψm preservation correlated with SIRT3 and Bcl-2 upregulation. In neuronal ROS models (H&sub2;O&sub2;/rotenone), spirulina reduced TUNEL-positive cells 30–45%. Human surrogate data: 4–8 g/day spirulina reduces serum 8-OHdG (DNA oxidation marker; p53 activator) 20–35% and CRP 20–40%, consistent with reduced pro-apoptotic stress. Interactions: chemotherapy agents (inducing apoptosis in cancer cells) — theoretical concern that spirulina’s anti-apoptotic effects could protect tumour cells; insufficient evidence in humans; oncology patients should discuss with their oncologist before use.